[an error occurred while processing this directive]|[an error occurred while processing this directive]
原发性肝癌术后辅助治疗的研究进展
程书蕙, 陈波, 李晔雄
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科,100021
Research developments of adjuvant therapies for hepatocellular carcinoma after resection
Cheng Shuhui,Chen Bo,Li Yexiong
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences ( CAMS ) and Peking Union Medical College ( PUMC),Beijing 100021,China
Abstract： Hepatocellular carcinoma (HCC) is a common malignancy with high rate of morbidity and mortality.Liver resection is the most effective curative treatment,yet subsequent recurrence and death are common,with 5-year overall survival rate remaining about 50% and 5-year postoperative recurrence reaching as high as 60%-70% reported by previous publications. Therefore,it is essential to identify the optimal adjuvant therapy for patients with unfavorable prognostic factors to decrease the postoperative recurrence or metastasis,thereby to deliver the promise of improved outcomes. However,there is no consensus about it and several treatment options were under investigation,including transcatheter arterial chemoembolization (TACE),radiotherapy,targeted therapy,and other treatments. Here,we review studies on the role of adjuvant therapies,to provide evidences for further research and clinical practice.
Cheng Shuhui,Chen Bo,Li Yexiong. Research developments of adjuvant therapies for hepatocellular carcinoma after resection[J]. Chinese Journal of Radiation Oncology, 2019, 28(3): 233-237.
[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.DOI:10.3322/caac.21442. [2] Perz JF,Armstrong GL,Farrington LA,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol,2006,45(4):529-538.DOI:10.1016/j.jhep.2006.05.013. [3] Schwartz JD,Schwartz M,Mandeli J,et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma:review of the randomised clinical trials[J].Lancet Oncol,2002,3(10):593-603. [4] Llovet JM,Schwartz M,Mazzaferro V.Resection and liver transplantation for hepatocellular carcinoma[J].Semin Liver Dis,2005,25(2):181-200.DOI:10.1055/s-2005-871198. [5] Forner A,Llovet JM,Bruix J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.DOI:10.1016/S0140-6736(11)61347-0. [6] Imamura H,Matsuyama Y,Tanaka E,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J].J Hepatol,2003,38(2):200-207. [7] Torzilli G,Belghiti J,Kokudo N,et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers:is it adherent to the EASL/AASLD recommendations?:an observational study of the HCC East-West study group[J].Ann Surg,2013,257(5):929-937.DOI:10.1097/SLA.0b013e31828329b8. [8] Nara S,Shimada K,Sakamoto Y,et al. Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma:evidence from 570 hepatectomies[J].Surgery,2012,151(4):526-536.DOI:10.1016/j.surg.2011.12.002. [9] Chau GY,Lui WY,Tsay SH,et al. Prognostic significance of surgical margin in hepatocellular carcinoma resection:an analysis of 165 Childs′ A patients[J].J Surg Oncol,1997,66(2):122-126. [10] Shi M,Guo RP,Lin XJ,et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma:a prospective randomized trial[J].Ann Surg,2007,245(1):36-43.DOI:10.1097/01.sla.0000231758.07868.71. [11] Shimada K,Sakamoto Y,Esaki M,et al. Role of the width of the surgical margin in a hepatectomy for small hepatocellular carcinomas eligible for percutaneous local ablative therapy[J].Am J Surg,2008,195(6):775-781.DOI:10.1016/j.amjsurg.2007.06.033. [12] Ikai I,Arii S,Kojiro M,et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J].Cancer,2004,101(4):796-802.DOI:10.1002/cncr.20426. [13] Rodriguez-Peralvarez M,Luong TV,Andreana L,et al. A systematic review of microvascular invasion in hepatocellular carcinoma:diagnostic and prognostic variability[J].Ann Surg Oncol,2013,20(1):325-339.DOI:10.1245/s10434-012-2513-1. [14] Roayaie S,Blume IN,Thung SN,et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma[J].Gastroenterology,2009,137(3):850-855.DOI:10.1053/j.gastro.2009.06.003. [15] Chen WT,Chau GY,Lui WY,et al. Recurrent hepatocellular carcinoma after hepatic resection:prognostic factors and long-term outcome[J].Eur J Surg Oncol,2004,30(4):414-420.DOI:10.1016/j.ejso.2004.01.013. [16] Li ZL,Yu JJ,Guo JW,et al. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis:A multicenter analysis of 1,066 patients[J].Eur J Surg Oncol,2018.DOI:10.1016/j.ejso.2018.12.016. [17] Cho CS,Gonen M,Shia J,et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma[J].J Am Coll Surg,2008,206(2):281-291.DOI:10.1016/j.jamcollsurg.2007.07.031. [18] Chen XH,Zhang BH,Xin Y,et al. Risk factors for residual tumor after resection of hepatocellular carcinoma[J].World J Gastroenterol,2011,17(14):1889-1894.DOI:10.3748/wjg.v17.i14.1889. [19] Prospective validation of the CLIP score:a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators[J].Hepatology,2000,31(4):840-845.DOI:10.1053/he.2000.5628. [20] Hosaka T,Ikeda K,Kobayashi M,et al. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma[J].Liver Int,2009,29(5):736-742.DOI:10.1111/j.1478-3231.2008.01901.x [21] Furihata T,Sawada T,Kita J,et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy[J].Hepatogastroenterology,2008,55(86-87):1705-1709. [22] Hung IF,Poon RT,Lai CL,et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J].Am J Gastroenterol,2008,103(7):1663-1673.DOI:10.1111/j.1572-0241.2008.01872.x. [23] Yu SJ,Kim YJ.Hepatitis B viral load affects prognosis of hepatocellular carcinoma[J].World J Gastroenterol,2014,20(34):12039-12044.DOI:10.3748/wjg.v20.i34.12039. [24] Qu LS,Liu JX,Zhu J,et al. Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load[J].Ann Hepatol,2017,16(3):412-420.DOI:10.5604/16652681.1235484. [25] Sheu JC,Huang GT,Chou HC,et al. Multiple hepatocellular carcinomas at the early stage have different clonality[J].Gastroenterology,1993,105(5):1471-1476. [26] Chen PJ,Chen DS,Lai MY,et al. Clonal origin of recurrent hepatocellular carcinomas[J].Gastroenterology,1989,96(2 Pt 1):527-529. [27] Liu C, Sun L, Xu J, et al. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma[J]. World J Surg Oncol, 2016,14:100.DOI:10.1186/s12957-016-0855-z. [28] Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma[J]. Hepatology, 1994,20(2):295-301. [29] Sun J J, Wang K, Zhang C Z, et al. Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion[J]. Ann Surg Oncol, 2016,23(4):1344-1351.DOI:10.1245/s10434-015-5008-z. [30] Wang YY,Wang LJ,Xu D,et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion[J].HPB (Oxford),2018.DOI:10.1016/j.hpb.2018.08.001. [31] Zhong J H, Li L Q. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma:a meta-analysis[J]. Hepatol Res, 2010,40(10):943-953.DOI:10.1111/j.1872-034X.2010.00710.x. [32] Cheng X, Sun P, Hu Q G, et al. Transarterial (chemo) embolization for curative resection of hepatocellular carcinoma:a systematic review and meta-analyses[J]. J Cancer Res Clin Oncol, 2014,140(7):1159-1170.DOI:10.1007/s00432-014-1677-4. [33] Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma:a meta-analysis[J]. Scand J Gastroenterol, 2017,52(6-7):624-634.DOI:10.1080/00365521.2017.1292365. [34] Lai E C, Lo C M, Fan S T, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma:a randomized controlled trial[J]. Arch Surg, 1998,133(2):183-188. [35] Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC)[J]. Hepatogastroenterology, 1996,43(12):1405-1409. [36] Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma:a prospective randomized study[J]. Semin Oncol, 1997,24(2 Suppl 6):S6-S18. [37] 奚韬,闫振林,王葵.等.术后经导管动脉化疗栓塞对不同病理特征肝癌的抗复发作用[J].中华外科杂志,2007,45(9):587-590. DOI:10.3760/j.issn:0529-5815.2007.09.004. Zou T,Yan ZL,Wang K,et al. Anti-recurrence effect of postoperative transcatheter arterial chemoembolization on hepatocellular carcinoma with different pathological characteristics[J].Chin J Surg,2007,45(9):587-590. DOI:10.3760/j.issn:0529-5815.2007.09.004. [38] Klein J,Dawson LA.Hepatocellular carcinoma radiation therapy:review of evidence and future opportunities[J].Int J Radiat Oncol Biol Phys,2013,87(1):22-32.DOI:10.1016/j.ijrobp.2012.08.043. [39] Wang WH,Wang Z,Wu JX,et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J].Liver Int,2015,35(12):2603-2610.DOI:10.1111/liv.12857. [40] Wang L,Wang W,Yao X,et al. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion[J].Oncotarget,2017,8(45):79971-79981.DOI:10.18632/oncotarget.20402. [41] Lau WY,Leung TW,Ho SK,et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma:a prospective randomised trial[J].Lancet,1999,353(9155):797-801. [42] 饶建,林秀欣.原发性肝癌术后放疗的临床意义(附104例分析)[J].世界肿瘤杂志,2008,7(2).127-129.DOI:10.3969/j.issn.1672-5085.2009.20.012. Rao J,Lin XX. Clinical significance of postoperative radiotherapy for primary hepatocellular carcinoma (analysis of 104 cases)[J].Tumour J World,2008,7(2).127-129.DOI:10.3969/j.issn.1672-5085.2009.20.012. [43] 李明非,关华,甘险峰,等.原发性肝细胞癌切除术后放疗的临床价值[J].现代中西医结合杂志,2016,25(21):2343-2344.DOI:10.3969/j.issn.1008-8849.2016.21.022. Li MF,Guan H,Gan XF,et al. Clinical value of radiotherapy after primary hepatocellular carcinoma resection[J].2016,25(21):2343-2344.DOI:10.3969/j.issn.1008-8849.2016.21.022. [44] Llovet JM,Ricci S,Mazzaferro V,et al. Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.DOI:10.1056/NEJMoa0708857. [45] Cheng AL,Kang YK,Chen Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.DOI:10.1016/S1470-2045(08)70285-7. [46] Bruix J,Qin S,Merle P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,389(10064):56-66.DOI:10.1016/S0140-6736(16)32453-9. [47] Kudo M,Finn RS,Qin S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,391(10126):1163-1173.DOI:10.1016/S0140-6736(18)30207-1. [48] Bruix J,Takayama T,Mazzaferro V,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM):a phase 3,randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2015,16(13):1344-1354.DOI:10.1016/S1470-2045(15)00198-9. [49] Zhang W,Zhao G,Wei K,et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection:a single-center experience[J].Biosci Trends,2014,8(6):333-338.DOI:10.5582/bst.2014.01120. [50] Huang YH,Wu JC,Lui WY,et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma[J].World J Surg,2000,24(5):551-555. [51] Ono T,Yamanoi A,Nazmy EAO,et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients:metaanalysis of three randomized controlled trials[J].Cancer,2001,91(12):2378-2385. [52] Wong JS,Wong GL,Tsoi KK,et al. Meta-analysis:the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J].Aliment Pharmacol Ther,2011,33(10):1104-1112.DOI:10.1111/j.1365-2036.2011.04634.x. [53] Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial[J]. Ann Intern Med, 2001,134(10):963-967. [54] Lygidakis N J, Pothoulakis J, Konstantinidou A E, et al. Hepatocellular carcinoma:surgical resection versus surgical resection combined with pre-and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study[J]. Anticancer Res, 1995,15(2):543-550.
2019, Vol. 28 
